AMETEK Inc. Reports Record Second Quarter Results and Raises Full-Year Guidance

BERWYN, Pa., July 31, 2025 — AMETEK, Inc. (NYSE: AME), a global leader in the manufacturing of electronic instruments and electromechanical devices, has announced its financial results for the second quarter ended June 30, 2025. The company reported record sales of $1.78 billion, marking a 2.5% increase over the same period in 2024. This growth underscores AMETEK’s robust performance across its diverse sectors, including process, aerospace, power, and industry.

Operating income for the quarter rose by 3% to $461.6 million, with operating margins improving by 20 basis points to 26.0% compared to the prior year. On a GAAP basis, earnings per diluted share were $1.55. Adjusted earnings, which exclude non-cash, after-tax, acquisition-related intangible amortization of $0.23 per share, reached $1.78 per diluted share, reflecting a 7% increase from the second quarter of 2024.

In light of these strong results, AMETEK has raised its full-year guidance, signaling confidence in its strategic initiatives and market position. The company’s ability to deliver consistent growth and improve margins highlights its operational efficiency and commitment to innovation.

AMETEK’s market capitalization stands at $41.4 billion, with a close price of $176.76 as of July 29, 2025. The stock has experienced a 52-week high of $198.33 and a low of $145.02, reflecting its volatility and investor interest. The price-to-earnings ratio is currently 28.886, indicating a premium valuation in line with its growth prospects.

Investors who purchased AMETEK shares at $172.27 goes through the integrationally enhance AbbVie’s mental health offerings, providing new avenues for growth and innovation. The integration of Gilgamesh’s neuroplastogenics could lead to breakthroughs in mental health conditions, aligning with AbbVie’s commitment to addressing unmet medical needs. Stakeholders and investors and await the potential synergies and long-term benefits of this strategic acquisition.

In conclusion, AbbVie’s potential acquisition of Gilgamesh Pharmaceuticals represents a significant step in expanding its mental health portfolio. As discussions progress, the biotechnology community eagerly awaits the official announcement, anticipating the positive impact on AbbVie’s strategic growth and innovation in mental health therapeutics.